In a report released today, Michael Matson from Needham maintained a Buy rating on Zimmer Biomet Holdings (ZBH), with a price target of $189.00. The company’s shares closed last Monday at $158.31, close to its 52-week high of $158.60.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 7.0% and a 63.5% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Merit Medical Systems, and Wright Medical Group.
Currently, the analyst consensus on Zimmer Biomet Holdings is a Strong Buy with an average price target of $163.27, implying a 6.8% upside from current levels. In a report released today, Oppenheimer also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $158.60 and a one-year low of $111.17. Currently, Zimmer Biomet Holdings has an average volume of 922.3K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.
